• Bibliometrics
• Cardiovascular diseases
• Myocardial fibrosis
• Stem cells
• VOSviewer

• Cardiac diseases
• Cardiac stem cell
• Cell therapies
• Gene therapies

• Humans
• Genetic Therapy/methods
• Animals
• Myocytes, Cardiac/metabolism
• Myocytes, Cardiac/cytology
• Heart Diseases/therapy
• Heart Diseases/genetics
• Cell- and Tissue-Based Therapy/methods
• Gene Editing
• Cardiology/methods
• Stem Cell Transplantation/methods

Mesenchymal stem cells (MSC) have emerged as breakthrough treatments for myocardial infarction. However, the efficacy of MSC remains unclear. The aim of the study was to evaluate treatment effect of MSC in terms of mechanical, regenerative, and clinical outcomes for patients with myocardial infarction (MI) using meta-analysis.

A systematic search and critical review of MEDLINE, EMBASE, and Cochrane database literature published from inception through December 2017 was performed. The inclusion criteria were randomized controlled trials, studies on patients with myocardial infarction, and studies compared with placebo as a control group.

A total of 950 patients from 14 randomized placebo controlled trials were included in the final meta-analysis. MSC treatment showed benefits for mechanical, regenerative, and clinical outcomes. In terms of mechanical outcomes, the LVEF of the MSC treatment group increased by 3.84% (95% CI: 2.32~5.35, I²=43) and the effect was maintained for up to 24 months. Regenerative outcomes were measured by scar mass and WMSI. Scar mass was reduced by −1.13 (95% CI: −1.80 to −0.46, I²=71) and WMSI was reduced by −0.05 (95% CI: −0.07 to −0.03, I²=45) at 6 months after MSC treatment. Mortality rate and incidence of re-hospitalization for HF in MSC group patients trended toward reduced incidence compared to the control group, although this was not statistically significant because of the low event rate.

The findings of this meta-analysis indicate that MSCs can be beneficial in improving heart function in the treatment of MI. However, the efficacy of MSCs must be further explored through large randomized controlled trials based on rigorous research design.

• Mesenchymal stem cell
• Meta-analysis
• Myocardial infarction
• Systematic review

• Cardiac
• Mesenchymal stem cells

• embryonic stem cells
• induced pluripotent stem cells
• mesenchymal stem cells
• stem cell-based therapy.

• Cardiology
• Cardiovascular disease
• Clinical trial
• Mesenchymal stem cell
• Myocardial infarction

Complexity of the spatial configuration of an aortic implant with bifurcation in the distal part is related to changes in blood hemodynamic in the area of bifurcation which may disturb blood flow and lead to thrombus formation. This study was designed to characterize parameters which define spatial configuration of an aortic implant for which the risk of thrombus formation is the smallest. We used AngioCT data from 74 patients, aged 55 ±10 years, after endovascular procedure to prepare 3D geometries of stent-grafts. Computational Fluid Dynamics (CFD) simulations were used to reconstruct blood hemodynamic and simulate thrombus formation. Next, geometric parameters of stent-grafts included the ratio of volume of upper part to the bifurcations, the relation of inlet and outlet diameters of a stent-graft and deformations in the iliac part of the stent-graft were analyzed. We also analyzed tortuosities (spiral twisting of the flow around the flow direction) and bends (the largest angulation in distal part of a stent-graft). The CFD results were confronted with AngioCT data to verify if computer generated thrombus appeared in particular patient. Additionally, geometric parameters of analyzed stent-grafts were used to propose a mathematical tool for prediction of thrombus appearance. The results showed that tortuosities and bends of a stent-graft had the highest impact on thrombus formation. Formation of thrombi was observed in 22% to 31% of cases (at blood hematocrit Hct = 40%) even for small values of tortuosities and bends indicating that these parameters are dominant in determining blood clotting. Our calculated results overlapped with clinical data in 80% to 91%. Therefore, we conclude that tortuosities and bends have high impact on thrombus formation and should be under special attention during stent-graft recommendation and patients’ follow-ups.

• adipose-derived mesenchymal stem cells
• cellular crosstalk
• chitosan
• cytokine signalling
• electrical stimulation
• electrically conductive scaffold
• endothelial cells
• polypyrrole

• Animals
• Cell- and Tissue-Based Therapy/methods
• Humans
• Intestines/injuries
• Intestines/pathology
• Mesenchymal Stem Cell Transplantation/methods
• Mesenchymal Stem Cells/metabolism
• Reperfusion Injury/pathology
• Reperfusion Injury/therapy

• KL2 TR001106 NCATS NIH HHS
• T35 HL110854 NHLBI NIH HHS
• UL1 TR001108 NCATS NIH HHS

• Alternans
• Arrhythmia
• Mesenchymal stem cells
• Oxidative stress
• SERCA2a

• Bladder obstruction
• Immunomodulation
• Mesenchymal
• Renal fibrosis
• Stem cells
• Urinary incontinence

• Animals
• Fibrosis
• Humans
• Regeneration
• Stem Cell Transplantation
• Stem Cells
• Tissue Engineering
• Urologic Diseases/pathology
• Urologic Diseases/therapy

Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual efficacy of MSCs in various diseases has evoked a sense of discouragement. Therefore, we believe that MSC therapy may now be at a critical milestone for re-evaluation and re-consideration. In this review, we summarize the current status of MSC-based clinical trials and focus on the discrepancy between expected and actual outcome of MSC therapy from bench to bedside. Importantly, we discuss the underlying limitations of MSCs and suggest a new guideline for MSC therapy in hopes of improving their therapeutic efficacy.

• Clinical trial
• Immune modulation
• Limitation
• Mesenchymal stem cells

• Angiogenesis
• Chronic myocardial ischemia
• Mesenchymal stromal cell
• Refractory angina
• Stem cell
• Stem cell therapy

• Clinical trial
• Graft vs host disease
• Mesenchymal stromal cells
• Tissue therapy

• Animals
• Cell Differentiation
• Cell Lineage
• Cell Movement
• Cell Proliferation
• Gene Expression Regulation
• Humans
• Mesenchymal Stem Cell Transplantation/adverse effects
• Mesenchymal Stem Cells/immunology
• Mesenchymal Stem Cells/physiology
• Regeneration
• Regenerative Medicine/methods
• Treatment Outcome

While PDE5 inhibitors have revolutionized treatment of ED, approximately 30% of patients are non-responsive. A significant cause of this is vascular and smooth muscle dysfunction, as well as nerve atrophy. Autologous administration of bone marrow mononuclear cells (BMMC) has been performed in over 2000 cardiac patients without adverse effects, for stimulation of angiogenesis/regeneration. Despite its ease of access, and dependence on effective vasculature for function, comparatively little has been perform in terms of BMMC therapy for ED. Here we outline the rationale for use of autologous BMMC in patients with ED, as well as provide early safety data on the first use of this procedure clinically.

• biomaterials
• cardiac-tissue engineering
• injectable system
• myocardial infarction

• Animals
• Cells, Cultured
• Guided Tissue Regeneration/instrumentation
• Guided Tissue Regeneration/methods
• Humans
• Injections, Intralesional
• Minimally Invasive Surgical Procedures/methods
• Myocardial Ischemia/surgery
• Myocytes, Cardiac/transplantation
• Pericardium/surgery
• Tissue Engineering/instrumentation
• Tissue Engineering/methods
• Tissue Scaffolds

To reduce long-term morbidity after revascularised acute myocardial infarction, different therapeutic strategies have been investigated. Cell therapy with mononuclear cells from bone marrow (BMMC) or peripheral blood (PBMC) has been proposed to attenuate the adverse processes of remodelling and subsequent heart failure. Previous trials have suggested that cell therapy may facilitate arrhythmogenesis. In the present substudy of the HEBE cell therapy trial, we investigated whether intracoronary cell therapy alters the prevalence of ventricular arrhythmias after 1 month or the rate of severe arrhythmogenic events (SAE) in the first year. In 164 patients of the trial we measured function and infarct size with cardiovascular magnetic resonance (CMR) imaging. Holter registration was performed after 1 month from which the number of triplets (3 successive PVCs) and ventricular tachycardias (VT, ≥4 successive PVCs) was assessed. Thirty-three patients (20%) showed triplets and/or VTs, with similar distribution amongst the groups (triplets: control n = 8 vs. BMMC n = 9, p = 1.00; vs. PBMC n = 10, p = 0.67. VT: control n = 9 vs. BMMC n = 9, p = 0.80; vs. PBMC n = 11, p = 0.69). SAE occurred in 2 patients in the PBMC group and 1 patient in the control group. In conclusion, intracoronary cell therapy is not associated with an increase in ventricular arrhythmias or SAE.

Action potentials generated in the sinoatrial node (SAN) dominate the rhythm and rate of a healthy human heart. Subsequently, these action potentials propagate to the whole heart via its conduction system. Abnormalities of impulse generation and/or propagation in a heart can cause arrhythmias. For example, SAN dysfunction or conduction block of the atrioventricular node can lead to serious bradycardia which is currently treated with an implanted electronic pacemaker. On the other hand, conduction damage may cause reentrant tachyarrhythmias which are primarily treated pharmacologically or by medical device-based therapies, including defibrillation and tissue ablation. However, drug therapies sometimes may not be effective or are associated with serious side effects. Device-based therapies for cardiac arrhythmias, even with well developed technology, still face inadequacies, limitations, hardware complications, and other challenges. Therefore, scientists are actively seeking other alternatives for antiarrhythmic therapy. In particular, cells and genes used for repairing cardiac conduction damage/defect have been investigated in various studies both in vitro and in vivo. Despite the complexities of the excitation and conduction systems of the heart, cell and gene-based strategies provide novel alternatives for treatment or cure of cardiac arrhythmias. This review summarizes some highlights of recent research progress in this field.

• arrhythmia
• cell therapy
• conduction repair
• gene therapy

Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6 million. Despite the development of a variety of treatment options, heart failure management has failed to inhibit myocardial scar formation and replace the lost cardiomyocyte mass with new functional contractile cells. This shortage is complicated by the limited ability of the heart for self-regeneration. Accordingly, novel management approaches have been introduced into the field of cardiovascular research, leading to the evolution of gene- and cell-based therapies. Stem cell-based therapy (aka, cardiomyoplasty) is a rapidly growing alternative for regenerating the damaged myocardium and attenuating ischemic heart disease. However, the optimal cell type to achieve this goal has not been established yet, even after a decade of cardiovascular stem cell research. Mesenchymal stem cells (MSCs) in particular have been extensively investigated as a potential therapeutic approach for cardiac regeneration, due to their distinctive characteristics. In this paper, we focus on the therapeutic applications of MSCs and their transition from the experimental benchside to the clinical bedside.

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Coronary artery disease is a growing problem worldwide. Early treatment with stabilizing drugs and revascularization by percutaneous coronary intervention or by-pass surgery has reduced the mortality significantly, but it is still the most common cause of death and a major cause of hospital admissions in industrialized countries. Treatment with stem cells with the potential to regenerate the damaged myocardium is a relatively new approach. However, the results from clinical studies on stem cell therapy for cardiac regeneration in patients with acute or chronic ischemic heart disease have been inconsistent. Some of the discrepancy could be due differences in study designs or patient selection. The review will based on conducted clinical stem cell trials try to elucidate how to predict and personalize this new treatment approach.